Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunityOXFORD, United Kingdom, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greywolf Therapeutics, the clinical-stage biotech company advancing novel antigen modulation technology to guide the immune system, have successfully dosed the first healthy volunteer in their Phase 1/2 trial (NCT07047703) evaluating GRWD0715, an oral ERAP1 inhibitor, for the treatment of axial spondyloarthritis (axSpA).
Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer
Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star Therapeutics Inc. (FSTX), which she took public on the NASDAQ in 2020, through to the successful sale of the company in 2023.
